Phase II Study of SB1518 for Patients With Myelodysplastic Syndrome (MDS).
Phase of Trial: Phase II
Latest Information Update: 16 Jun 2016
At a glance
- Drugs Pacritinib (Primary)
- Indications Myelodysplastic syndromes
- Focus Therapeutic Use
- 01 Jun 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 26 Jan 2012 Status changed from recruiting to active, no longer recruiting as reported by M.D. Anderson Cancer Center record.
- 26 Jan 2012 New source identified and integrated (M.D. Anderson Cancer Center).